{"id":"NCT02013622","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia","officialTitle":"Protocol 331-13-006: An Exploratory, Multicenter, Open-label, Monotherapy, Flexible-dose Brexpiprazole (OPC 34712) Trial in Adults With Early Episode Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11","primaryCompletion":"2014-09","completion":"2014-10","firstPosted":"2013-12-17","resultsPosted":"2016-03-29","lastUpdate":"2016-03-29"},"enrollment":49,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Brexpiprazole","otherNames":[]}],"arms":[{"label":"Brexpiprazole","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to investigate the effects of flexibly dosed Brexpiprazole monotherapy in the improvement of early-episode schizophrenia through the assessment of social functioning, efficacy, and tolerability. Early-episode schizophrenia is defined as episodes occurring â‰¤ 5 years after the onset of the first episode.","primaryOutcome":{"measure":"Mean Change From Baseline to Week 16 in Positive and Negative Syndrome Scale (PANSS) Total Score","timeFrame":"Baseline and Week 16","effectByArm":[{"arm":"Brexpiprazole","deltaMin":-10.2,"sd":2.1}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":22,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":49},"commonTop":["Insomnia","Somnolence","Nausea","Weight increased","Sedation"]}}